文献速递血管炎

抗CD19 CAR-T细胞疗法治疗ANCA相关性血管炎

Anti CD19 targeting CAR T cell therapy in ANCA-associated vasculitis.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

本文报告一例69岁男性复发性肉芽肿性多血管炎(GPA)患者,对多种免疫抑制治疗难治,接受抗CD19 CAR-T细胞实验性治疗后耐受良好,无细胞因子释放综合征或神经毒性,临床、影像和实验室指标快速改善,12个月随访时达完全缓解且无需用药。

要点

  • 抗CD19 CAR-T细胞疗法在难治性复发性GPA中安全有效
  • 治疗后无细胞因子释放综合征和神经毒性
  • 12个月随访达完全缓解且无需药物治疗

核心结论

  • 抗CD19 CAR-T细胞疗法在复发性难治性GPA患者中安全有效。
  • CAR-T细胞疗法有潜力改变疾病管理并改善患者长期结局。

研究设计与样本

  • 个案研究:一例69岁男性复发性GPA患者,对标准化免疫抑制治疗难治,接受抗CD19 CAR-T细胞实验性治疗。
  • 预处理方案为氟达拉滨和环磷酰胺。
  • 随访间隔为1至3个月,评估BVAS、肺部CT、CRP、外周白细胞计数、乳酸脱氢酶、ANCA、免疫球蛋白水平及CAR-T细胞计数。

主要发现

  • 患者2019年诊断为GPA累及肺部,尽管接受利妥昔单抗、环磷酰胺、avacopan、硫唑嘌呤、来氟米特和泼尼松龙治疗,仍表现为复发性难治性病程。
  • 接受CAR-T治疗时BVAS为14,炎症标志物升高,CT可见肺部浸润。
  • CAR-T细胞疗法耐受良好,无细胞因子释放综合征或神经毒性,临床状况、影像学和实验室检查结果快速改善。
  • CAR-T细胞短暂扩增达峰值,约第90天外周血中不再可检测到。
  • 治疗后观察到显著B细胞耗竭和低丙种球蛋白血症,随后逐渐恢复。

临床怎么用

  • 对于复发性难治性GPA患者,抗CD19 CAR-T细胞疗法可作为实验性治疗选择。
  • 治疗后需监测CAR-T细胞计数、B细胞耗竭和免疫球蛋白水平,关注低丙种球蛋白血症的恢复。

局限性

  • 本文为单个病例研究,证据级别有限。
  • CAR-T细胞疗法在GPA中的安全性和有效性需更大样本研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To present a successful case study of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in a patient with relapsing granulomatosis with polyangiitis (GPA). METHODS: A 69-year-old male patient suffering from relapsing GPA refractory to standardized immunosuppression underwent an experimental therapy involving CD19-targeting CAR T cells. The conditioning regimen consisted of fludarabine and cyclophosphamide. Follow-up intervals scheduled at 1 to 3 months' intervals, incorporated evaluations of the BVAS, CT scans of the lungs, CRP, peripheral white blood cell count (WBC), lactate dehydrogenase, ANCA, immunoglobulin levels, post-CAR T-cell treatment surveillance including (CAR)-lymphocyte counts. RESULTS: The patient was diagnosed with GPA involving the lungs in 2019. He showed a relapsed refractory disease course in spite of treatment with rituximab, cyclophosphamide, avacopan, azathioprine, leflunomide and prednisolone. At presentation for CAR T-cell treatment, the BVAS was 14, inflammation markers were elevated, and pulmonary infiltrates were visible on the CT scan. CAR T-cell therapy was well-tolerated with no cytokine release syndrome (CRS) or neurotoxicity, and led to rapid improvement of clinical condition, as well as radiological and laboratory test results. CAR T cells expanded with a transient peak but were not anymore detectable in the peripheral blood around day 90. In line the significant B-cell depletion and hypogammaglobulinemia observed post-treatment showed gradual recovery. At the latest follow-up of 12-months post-treatment, the patient is in complete remission without further medication. CONCLUSION: CD19-targeted CAR T-cell therapy was safe and efficacious in a patient with relapsed and refractory GPA. CAR T-cell therapy has the potential to transform disease management and improve long-term outcomes for affected patients.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Schneider L, Pecher AC, Hensen L, et al. Anti CD19 targeting CAR T cell therapy in ANCA-associated vasculitis. Rheumatology (Oxford). 2026. PMID: 41834136. doi:10.1093/rheumatology/keag126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。